BIOCORP, Merck KGaA Partner on Mallya Drug Delivery Accessory

BIOCORP, a French company specialized in the development, and manufacturing of innovative medical devices, and Merck KGaA, Darmstadt, Germany, a science, and technology company, have entered into an agreement for the development and supply of a specific version of Mallya device as an accessory for one of Merck KGaA, Darmstadt, Germany’s drug delivery devices.
 
Mallya is a Bluetooth enabled clip-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya is the first in its category to receive the CE-mark and commercial versions for insulin pen injectors are currently available in Europe and other geographies. BIOCORP has entered major agreements with Sanofi, Novo Nordisk and Merck KGaA, Darmstadt, Germany, to develop specific versions of the technology in the field of Insulin and Human Growth Hormone (HGH).
 
BIOCORP and Merck KGaA will develop a new version of Mallya to help patients monitor their injection during their treatment. The device automatically keeps track of doses injected with timestamp and indicate that the product is administered properly.
 
Merck KGaA will pay as much as €5 million for the development of the product within the first three years of the collaboration, and as much as €8 million during the first five years after launch depending on commercial milestones and adoption of Mallya devices by Merck KGaA patients.
 
“We are delighted with this new partnership with Merck KGaA, Darmstadt, Germany, extending our collaboration to additional therapeutic areas. We had already announced that there is a great opportunity for our connected device Mallya in various therapeutic areas. As in diabetes, Mallya aims to reduce patients’ stress and improve compliance with their treatments to optimize and secure the results,” said Éric Dessertenne, CEO of BIOCORP.